DV

Daniel Vasella

Europe, Basel-Stadt, Switzerland, Basel

Description

Daniel Vasella is the Chairman Of The Board at Numab Therapeutics AG.

Investor Profile

Daniel Vasella has backed more than 2 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 0 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series C, Series A rounds (top funding stages).
  • Majority of deals are located in Ghana, Switzerland.
  • Strong thematic focus on Health Care, Pharmaceutical, Hospital.

Stage Focus

  • Series C (50%)
  • Series A (50%)

Country Focus

  • Ghana (50%)
  • Switzerland (50%)

Industry Focus

  • Health Care
  • Pharmaceutical
  • Hospital
  • Biotechnology
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Daniel Vasella frequently co-invest with?

Unbound
Europe, England, United Kingdom, London
Co-Investments: 1
Acuity Ventures
North America, California, United States, San Jose
Co-Investments: 1
AV
Europe, Istanbul, Turkey, Istanbul
Co-Investments: 1
Novartis Venture Fund
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 1
DOMPE
Europe, Lombardia, Italy, Milan
Co-Investments: 1
northstar.vc
Europe, England, United Kingdom, London
Co-Investments: 1
JF
North America, California, United States, Los Angeles
Co-Investments: 1
Novastar Ventures
Africa, Nairobi Area, Kenya, Nairobi
Co-Investments: 1
CDC Group
Europe, England, United Kingdom, London
Co-Investments: 1
Breyer Capital
North America, California, United States, Menlo Park
Co-Investments: 1

Which angels does Daniel Vasella often collaborate with?

JB
North America, California, United States, Menlo Park
Shared Deals: 1
CG
Europe, England, United Kingdom, London
Shared Deals: 1
RA
Europe, Basel-Stadt, Switzerland, Basel
Shared Deals: 1

What are some of recent deals done by Daniel Vasella?

mPharma

Accra, Greater Accra, Ghana

mPharma offers solutions to health insurance and pharmaceutical companies to make it easier for patients to afford their medications.

Health CareHospitalPharmaceutical
Series CMay 26, 2020
Amount Raised: $18,520,000
ImmunOs Therapeutics

Schlieren, Zurich, Switzerland

ImmunOs Therapeutics is a clinical-stage biotechnology company.

BiotechnologyHealth CarePharmaceutical
Series ADec 10, 2019
Amount Raised: $15,235,015